Bennett MacGregor

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.
Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison and paid for it.
But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

@HatedMoats But they don't need a knockout clear winner. They need an efficacious alternative that people can actually get (cost, supply, access).
This feels more like sentiment damage than thesis damage.

[Bennett MacGregor @BennettMacG]

@HatedMoats CagriSema is a completely different mechanism than anything else out there right now.
Yeah it came up short vs tirzepatide on pure weight loss, but 23% average weight loss is still absolutely insane.
People are acting like that's bad medicine. It's not.

[Bennett MacGregor @BennettMacG]

@HatedMoats Because it's a different pathway, it could absolutely help people who've plateaued on straight GLP-1s. Not everyone responds the same. There's room for alternatives.
lagree the study design and narrative from NVO was dumb. They set themselves up for a direct comparison.

[unusual_whales @unusual_whales]

The American dream of owning a home is slipping out of reach as affordability hits its worst point in nearly four decades, per Bloomberg.

[Sabo @BrianSabo52]

Hearing that the ol’ chunk of coal Norm Macdonald has left us is the saddest news I’ve heard in the past 6 years

[Breese Hill @breeseh13]

Ginger ale is the nectar of the gods

[Dogecoin Rise 🌎🚀🌕 @DogecoinRise]

Retweet For $0.06 #dogecoin 🚀🚀🚀

[sean paradis @bluedevil4484]

Nice to see Jackson getting an offer from UMASS! Great school, great staff, and the same school my father played for!
#hardworkpaysoff! #BLN

[Nashoba Boys’ Lacrosse @NRHSBoysLax]

Today’s clip is a textbook right to left downhill dodge with a SMOOTH off-hand finish for #7!

[Only In Boston @OnlyInBOS]

Today is the shortest day of 2018.

Today will have 9:04:38 hours of daylight.

Daylight will increase each day until the Summer Solstice in June.

From here on out, it's going to be more...lit.

🌞

[Bennett MacGregor @BennettMacG]

#metoo

[Only In Boston @OnlyInBOS]

Massachusetts invented America.

Please remind the haters.

🇺🇸